6 March 2024 · Introducing biosimilar eculizumab needs planning. Work with the multidisciplinary team to ensure familiarity with the area and develop an implementation plan.
29 June 2022 · Governance should consider processes for approval; procurement and supply; prescribing and administration; monitoring; and pharmacovigilance
29 June 2022 · Four licensed ranibizumab biosimilars are available: Byooviz, Ongavia, Rimmyrah and Ximluci. Learn about the licensed indications and supporting evidence
2 August 2024 · Governance should consider processes for approval, procurement and supply, prescribing and administration, monitoring, and pharmacovigilance.
16 July 2024 · Introducing biosimilar ustekinumab needs planning. Work with the multidisciplinary team to ensure familiarity with the area and develop an implementation plan.
2 August 2024 · Ustekinumab biosimilars (Pyzchiva, Steqeyma, Uzpruvo, Wezenla) are licensed. Learn about indications, formulations, supporting evidence and differences.
11 July 2025 · Patents allow the inventor a finite period of monopoly in exchange for publicising the idea. We explain how they work with respect to medicines.